Cargando…
EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia
Accumulating studies have proved EZH2 dysregulation mediated by mutation and expression in diverse human cancers including AML. However, the expression pattern of EZH2 remains controversial in acute myeloid leukaemia (AML). EZH1/2 expression and mutation were analysed in 200 patients with AML. EZH2...
Autores principales: | Chu, Ming‐qiang, Zhang, Ting‐juan, Xu, Zi‐jun, Gu, Yu, Ma, Ji‐chun, Zhang, Wei, Wen, Xiang‐mei, Lin, Jiang, Qian, Jun, Zhou, Jing‐dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6991666/ https://www.ncbi.nlm.nih.gov/pubmed/31794134 http://dx.doi.org/10.1111/jcmm.14855 |
Ejemplares similares
-
Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms
por: Zhang, Qi, et al.
Publicado: (2019) -
Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia
por: Zhou, Jing-dong, et al.
Publicado: (2018) -
Dysregulation of haematopoietic stem cell regulatory programs in acute myeloid leukaemia
por: Basilico, Silvia, et al.
Publicado: (2017) -
Chronic myeloid leukaemia with marked thrombocytosis
por: Ooi, Jun, et al.
Publicado: (2020) -
EZH2 in Myeloid Malignancies
por: Rinke, Jenny, et al.
Publicado: (2020)